Aokang: Subsidiary innovative drug Maltol Iron Capsules receives notice of acceptance for drug registration and market approval application.

Announcement from Ausican: its wholly-owned subsidiary, Jiangsu Ausican Pharmaceuticals Co., Ltd., recently received the "Acceptance Notice" for the application for registration and market approval of overseas manufactured drug Maltol Iron Capsules issued by the National Medical Products Administration. The Maltol Iron Capsules, developed by UK company Shield TX Limited, were approved for marketing by the European Medicines Agency and the US Food and Drug Administration in 2016 and 2019 respectively for the treatment of adult iron deficiency. In December 2025, the US FDA approved the expansion of the age range to include children aged 10 and above for the treatment of iron deficiency in addition to adults. The subsidiary reached a cooperation agreement with Shield TX Limited in 2020, obtaining exclusive rights for the development, production, and marketing of Maltol Iron Capsules and its potential expanded dosage forms and indications in the People's Republic of China. The subsidiary has completed clinical trials of Maltol Iron Capsules in China, and recently submitted an application for import registration and market approval, which has been accepted.